953411-16-0

Basic information

• Product Name: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine
• Synonyms: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine;5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-aMi;(3-AMINO-1H-INDAZOL-5-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 953411-16-0
• Molecular Formula: C13H18BN3O2
• Molecular Weight: 259
• Mol File: 953411-16-0.mol

Chemical Properties

• Boiling Point: 469.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 14.90±0.40(Predicted)
• CAS DataBase Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine(953411-16-0)
• EPA Substance Registry System: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine(953411-16-0)

Safety Data

• Hazardous Substances Data: 953411-16-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine is used as a synthetic intermediate for the preparation of purineor pyrazolo[3,4-d]pyrimidine-linked isochromene derivatives. These derivatives are of significant interest as they act as phosphoinositide 3-kinase (PI3K) inhibitors.
PI3K inhibitors are a class of compounds that target the PI3K enzyme, which plays a crucial role in cell growth, proliferation, and survival. Overactivity or mutation of the PI3K pathway is implicated in various cancers and other diseases, making PI3K a key target for therapeutic intervention. By inhibiting this enzyme, these isochromene derivatives have the potential to treat cancer and other PI3K-related disorders, thus highlighting the importance of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine in the development of novel pharmaceutical agents.

Relevant articles and documents

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed herein are kinase inhibitor compounds having the structure (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, L, Q, and Y are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

ANTIMICROBIAL 4-OXOQUINOLIZINES

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful again